WO2014150983A3 - Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9) - Google Patents

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9) Download PDF

Info

Publication number
WO2014150983A3
WO2014150983A3 PCT/US2014/024702 US2014024702W WO2014150983A3 WO 2014150983 A3 WO2014150983 A3 WO 2014150983A3 US 2014024702 W US2014024702 W US 2014024702W WO 2014150983 A3 WO2014150983 A3 WO 2014150983A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
binding proteins
pcsk9
polypeptides
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/024702
Other languages
French (fr)
Other versions
WO2014150983A2 (en
Inventor
Chadwick Terence King
Simon Mark Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to AU2014235430A priority Critical patent/AU2014235430A1/en
Priority to US14/777,371 priority patent/US20160039945A1/en
Priority to CA2906508A priority patent/CA2906508A1/en
Priority to EP14724826.4A priority patent/EP2970501A2/en
Priority to JP2016501610A priority patent/JP2016514668A/en
Publication of WO2014150983A2 publication Critical patent/WO2014150983A2/en
Publication of WO2014150983A3 publication Critical patent/WO2014150983A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting PCSK9 binding to LDLR. In embodiments, the antigen binding proteins specifically bind PCSK9. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind PCSK9 Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from hypercholesterolemia and related disorders or conditions.
PCT/US2014/024702 2013-03-15 2014-03-12 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 Ceased WO2014150983A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2014235430A AU2014235430A1 (en) 2013-03-15 2014-03-12 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9)
US14/777,371 US20160039945A1 (en) 2013-03-15 2014-03-12 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
CA2906508A CA2906508A1 (en) 2013-03-15 2014-03-12 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP14724826.4A EP2970501A2 (en) 2013-03-15 2014-03-12 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
JP2016501610A JP2016514668A (en) 2013-03-15 2014-03-12 Human antigen-binding protein that binds to the proprotein convertase subtilisin keksin type 9

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798970P 2013-03-15 2013-03-15
US61/798,970 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014150983A2 WO2014150983A2 (en) 2014-09-25
WO2014150983A3 true WO2014150983A3 (en) 2014-12-04

Family

ID=50733300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/024702 Ceased WO2014150983A2 (en) 2013-03-15 2014-03-12 Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9

Country Status (6)

Country Link
US (1) US20160039945A1 (en)
EP (1) EP2970501A2 (en)
JP (1) JP2016514668A (en)
AU (1) AU2014235430A1 (en)
CA (1) CA2906508A1 (en)
WO (1) WO2014150983A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
CN112812184A (en) 2011-02-25 2021-05-18 中外制药株式会社 Fc gamma RIIb specific Fc antibodies
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Ways to treat or prevent cholesterol disorders
CN109517059B (en) 2011-06-30 2023-03-28 中外制药株式会社 Heterodimerised polypeptides
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
JP6124800B2 (en) 2011-11-30 2017-05-10 中外製薬株式会社 Medicament containing carrier (carrier) into cells forming immune complex
TW202237660A (en) 2012-08-24 2022-10-01 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
KR101860280B1 (en) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN114773470A (en) 2015-02-05 2022-07-22 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
EP3973958A3 (en) * 2015-03-20 2022-06-22 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
CN105037554B (en) * 2015-06-12 2019-04-12 成都贝爱特生物科技有限公司 The preparation and application thereof of anti-human PCSK9 antibody
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
HK1257102A1 (en) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
JP7032662B2 (en) * 2015-12-31 2022-03-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド PCSK9 antibody, its antigen-binding fragment and pharmaceutical use
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
TWI693940B (en) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Composition for the treatment or prevention of IL-8 related diseases
CA3035875A1 (en) 2016-09-20 2018-03-29 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders
US20190358411A1 (en) 2017-01-17 2019-11-28 Amgen Inc. Injection devices and related methods of use and assembly
CN107698679B (en) * 2017-01-22 2019-03-01 北京东方百泰生物科技有限公司 Anti- PCSK9 monoclonal antibody
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
BR112019020148A2 (en) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptide
EP3630157A4 (en) * 2017-05-31 2021-01-13 North Carolina Central University OPTIMIZATION OF AN ACTIVE PCSK9 DOSAGE
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. Drug delivery device with container access system and related method of assembly
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
MA50527A (en) 2017-11-03 2020-09-09 Amgen Inc SYSTEM AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHODS OF USE
MX2020004996A (en) 2017-11-16 2020-08-27 Amgen Inc Door latch mechanism for drug delivery device.
EP3835321A4 (en) 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN BINDING MOLECULE AND USE THEREOF
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
MX2021013441A (en) 2019-05-15 2021-12-10 Chugai Pharmaceutical Co Ltd An antigen-binding molecule, a pharmaceutical composition, and a method.
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
CN115124424B (en) * 2022-06-01 2024-04-05 重庆市食品药品检验检测研究院 Fenofibrate hapten, preparation method thereof, fenofibrate antigen, antibody and application thereof
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2009055783A2 (en) * 2007-10-26 2009-04-30 Schering Corporation Anti-pcsk9 and methods for treating lipid and cholesterol disorders
WO2010029513A2 (en) * 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Pcsk9 antagonists
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2009055783A2 (en) * 2007-10-26 2009-04-30 Schering Corporation Anti-pcsk9 and methods for treating lipid and cholesterol disorders
WO2010029513A2 (en) * 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Pcsk9 antagonists
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [Online] 2 February 2012 (2012-02-02), "Human angiopoietin-2 (Ang-2) antibody heavy chain variable region SEQ:45.", XP002727666, retrieved from EBI accession no. GSP:AZQ43949 Database accession no. AZQ43949 *
DATABASE Geneseq [Online] 23 July 2009 (2009-07-23), "Human nicotine specific antibody related protein, SEQ ID 85.", XP002727665, retrieved from EBI accession no. GSP:AXB70134 Database accession no. AXB70134 *

Also Published As

Publication number Publication date
AU2014235430A1 (en) 2015-09-24
CA2906508A1 (en) 2014-09-25
US20160039945A1 (en) 2016-02-11
EP2970501A2 (en) 2016-01-20
WO2014150983A2 (en) 2014-09-25
JP2016514668A (en) 2016-05-23

Similar Documents

Publication Publication Date Title
WO2014150983A3 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2014144080A3 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
WO2013181634A3 (en) Antigen binding proteins that bind pd-l1
HK1208236A1 (en) Antigen binding proteins that bind ccr2
HK1221964A1 (en) Antigen binding proteins that bind pd-1
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
WO2013173761A3 (en) St2 antigen binding proteins
MX2008009886A (en) Antibodies that bind par-2.
EA201590370A1 (en) ANTIBODIES TO PCSK9 WITH PH-DEPENDENT BINDING CHARACTERISTICS
EA201391157A1 (en) PCTA9 ANTAGONISTS
EA201000356A1 (en) ANTIGEN-BINDING PROTEINS CONNECTING WITH PROPROTEIN WITH SUBTILYSINE CONEXTASE KEXIN TYPE 9 (PCSK9)
EP3447074A3 (en) Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
JO3244B1 (en) Proteins bind to human IL-23 antigens
HK1204981A1 (en) Antibodies to matrix metalloproteinase 9
EP3670534A3 (en) Human fgf receptor and beta-klotho binding proteins
EA201490470A1 (en) ANTIBODIES TO PCSK9 AND THEIR APPLICATION
EA201890928A1 (en) ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR
WO2014197752A8 (en) Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
EA200801621A1 (en) ANTIBODIES DIRECTED ON HER-3 AND THEIR APPLICATION
EA201690503A1 (en) ANTIBODIES
WO2015117088A3 (en) Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
HK1208474A1 (en) Antigen binding proteins that bind egfr
HK1206038A1 (en) Antigen binding protenins that bind dll-4
WO2015160858A3 (en) Antigen binding proteins that bind wisp1
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14724826

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2906508

Country of ref document: CA

Ref document number: 2016501610

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014235430

Country of ref document: AU

Date of ref document: 20140312

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014724826

Country of ref document: EP